Provides benefits that intermediate risk patients need — unsurpassed hemodynamics, reliable performance and an excellent safety profile.
EVOLUT™ R TAVR
A Groundbreaking Study of Intermediate Risk Symptomatic Severe Aortic Stenosis Patients
Clinical data from the legacy CoreValve platform, demonstrating sustained valve performance out to five years1
Shorter hospital stays and faster functional recovery times for patients treated with TAVR vs. SAVR.
Supra-annular valve design maximizes leaflet coaptation and promotes single-digit gradients and large EOAs
Excellent early outcomes at 30 days that persist out through 24 months
All rights reserved. Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic.
™*Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.
Barbanti, et al., J Am Coll Cardiol Intv 2015; 8: 1084-91.